论文部分内容阅读
目的:探究阿德福韦酯联合拉米夫定治疗乙型病毒性肝炎的效果。方法:选取该院2013年11月至2015年11月收治的92例乙型病毒性肝炎患者,将其随机分成观察组和对照组,各46例。观察组通过阿德福韦酯联合拉米夫定治疗,对照组给予拉米夫定治疗,对比两组患者的丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、乙型病毒滴度(HBV-DNA)等相关指标的变化。结果:两组患者ALT、AST、HBV-DNA进行比较,差异均有统计学的意义(P<0.05)。治疗180 d,观察组和对照组HBV-DNA转阴率分别为26.09%、84.78%,差异有统计学的意义(P<0.05)。但两组患者不良反应发生率、HBeAb转阳率比较,差异均没有统计学的意义(P>0.05)。结论:乙型病毒性肝炎通过阿德福韦酯联合拉米夫定治疗,临床效果较佳,值得临床方面应用和推广。
Objective: To investigate the effect of adefovir dipivoxil combined with lamivudine in the treatment of hepatitis B virus. Methods: A total of 92 cases of hepatitis B patients admitted from November 2013 to November 2015 in our hospital were randomly divided into observation group (46 cases) and control group (46 cases). The observation group was treated with adefovir dipivoxil and lamivudine, while the control group was treated with lamivudine. The levels of ALT, AST, B virus titer (HBV-DNA) and other related indicators of change. Results: The differences of ALT, AST and HBV-DNA between the two groups were statistically significant (P <0.05). After 180 days of treatment, the negative rates of HBV-DNA in observation group and control group were 26.09% and 84.78%, respectively, with statistical significance (P <0.05). However, the incidence of adverse reactions and HBeAb positive rate in both groups were not statistically significant (P> 0.05). Conclusion: Hepatitis B through adefovir dipivoxil combined with lamivudine treatment, clinical effect is better, it is worth the clinical application and promotion.